Other languages Theriva Biologics, Inc.

Equities

TOVX

US87164U4094

Delayed Nyse Other stock markets 01:14:00 2024-04-24 pm EDT			5-day change	1st Jan Change
0.3601 ^USD	-4.46%		-17.22%	-16.28%

Apr. 23	Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma	CI
Mar. 25	Transcript : Theriva Biologics, Inc., 2023 Earnings Call, Mar 25, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma	Apr. 23
Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma	Feb. 07
Theriva Biologics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Theriva?? Biologics and Sant Joan de Deu-Bar Barcelona Children's Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer	Nov. 02
Theriva? Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023	23-10-23
Theriva Biologics, Inc. Announces Presentation at Esmo Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating Vcn-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck	23-10-17
Theriva Biologics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08
Theriva Biologics Announces Key Progress in Virage, an Ongoing, Multinational Phase 2B Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma	23-08-02
Potential US Curbs on AI Chip Exports to China Drag Sentiment, Driving Premarket Losses for US Equity Futures	23-06-28
Top Premarket Gainers	23-06-28
Theriva Biologics Says US FDA Grants Orphan Drug Designation to VCN-01 for Pancreatic Cancer Treatment; Shares Surge	23-06-27
Theriva Biologics Appoints Ramon Alemany as Senior VP of Discovery	23-05-23
Theriva Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Theriva Biologics anuncia la presentación de los datos de la cohorte 1 del ensayo clínico de fase Ib/IIa de SYN-004 (ribaxamasa) en receptores de trasplantes alogénicos de células hematopoyéticas	23-04-13
Theriva Biologics presenta los aspectos operativos más destacados y los resultados financieros del cuarto trimestre y del ejercicio 2022	23-03-31
Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30
Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30
Theriva Biologics reprograma la teleconferencia y el webcast para comentar los resultados financieros y operativos más destacados del cuarto trimestre y de todo el año 2022	23-03-25
Theriva Biologics realizará una teleconferencia y retransmisión por Internet para comentar los aspectos operativos más destacados y los resultados financieros del cuarto trimestre y del ejercicio 2022	23-03-20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Theriva Biologics, Inc.

Equities

TOVX

US87164U4094

Other languages

Filters